Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
Profesionales de la salud / / / /
ABVD vs. Stanford V vs. MOPP-EBV-CAD in advanced Hodgkin's lymphoma. Final results of the IIL HD9601 randomized trial
Presenter: M. FedericoPresenter's Affiliation: Intergruppo Italiano LinfomiType of Session: ScientificBackground The standard treatment for advanced Hodgkin's lymphoma (HL) is ABVD chemotherapy 30% of patients with advanced HL do not respond to...
Association between androgen deprivation therapy and fracture risk: A population-based cohort study in men with non-metastatic prostate cancer.
Presenter: M.R. SmithPresenter's Affiliation: Massachusetts General HospitalType of Session: ScientificBackground Several small retrospective studies have reported that GnRH agonists increase fracture risk in prostate patients. However, the...
Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips
The cDNA arrays and Gene Chips discussed in this study have not been approved by the FDA for use in patients. Presenter: Lajos PusztaiPresenter's Affiliation: M.D. Anderson Cancer Center, Houston, TXType of Session: ScientificBackground Gene...
Does postoperative radiotherapy after radical prostatectomy improve progression-free survival in pT3N0 prostate cancer? (EORTC 22911)
Presenter: M. BollaPresenter's Affiliation: CHR de Grenoble, Grenoble, FranceType of Session: ScientificBackground A significant number of patients with clinical T1-2N0M0 prostate cancer are treated with radical prostatectmy. ...
Effect of the addition of rituximab to front line therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) on the remission rate and time to treatment failure (TTF) compared to CHOP alone in mantle cell lymphoma (MCL): results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
This study discusses an off-label use of rituximab for the treatment of MCL. Presenter: W. HiddemannPresenter's Affiliation: Ludwig-Maximilians-University, Munchen, GermanyType of Session: ScientificBackground Mantle cell lymphoma (MCL) accounts for...
Monitoring circulating tumor cell (CTC) levels to predict rapid progression in metastatic breast cancer (MBC): a prospective, multi-institutional trial
Presenter: D.F. HayesPresenter's Affiliation: University of Michigan Comprehensive Cancer Center, Ann Arbor, MIType of Session: ScientificBackground The identification of markers that predict resistance to a treatment early in the course of therapy...
MRI detection of multi focal breast carcinoma: Report from the International Breast MRI Consortium
Presenter: M. D. SchnallPresenter's Affiliation: University of PennsylvaniaType of Session: ScientificBackground Single institution studies have suggested that MRI more accurately determines the extent of cancer within the breast compared...
Phase II trial of bevacizumab and erlotinib in patients with metastatic renal carcinoma (RCC)
This presentation discusses off-label use of bevacizumab for RCC. It also discusses the use of erlotinib for the treatment of RCC which has not been approved by the FDA. Presenter: J.D. HainsworthPresenter's Affiliation: Sarah Cannon Cancer...
Prediction of the therapeutic response to paclitaxel by gene expression profiling in neoadjuvant chemotherapy for breast cancer
Presenter: M. YoshimotoPresenter's Affiliation: Cancer Institute Hospital, Tokyo, JapanType of Session: ScientificBackground Many breast cancer patients receive chemotherapy as part of their treatment program A common chemotherapeutic agent used...
Randomized intergroup trial of first line treatment for patients </= 60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab- early stopping after the first interim analysis
This study discusses an off-label use of rituximab for the treatment of NHL. Presenter: M. G. PfreundschuhPresenter's Affiliation: International Intergroup: Germany, Australia, Sweden, UK, Czech Republic, Canada, Poland, ItalyType of Session:...
Results of E1496: A phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL)
This presentation discusses the off-label use of rituximab for the treatment of indolent NHL. Presenter: H.S. HochsterPresenter's Affiliation: ECOG/CALGBType of Session: ScientificBackground Indolent lymphomas (IL), as the name implies, have a...
The impact of a delay in initiating radiation therapy on prostate-specific antigen outcome for patients with clinically localized prostate cancer
Presenter: P.L. NguyenPresenter's Affiliation: Harvard Medical School/ University of PennsylvaniaType of Session: ScientificBackground It has been demonstrated that prolonged delay between cancer diagnosis and the start of radiation therapy (RT) is...
What we learned on June 5, 2004
The American Society of Clinical Oncology meeting was a wealth of information today. The take home message of what saw yesterday is discussed below and organized by disease type. Detailed coverage of the abstracts can be found on OncoLink for CME...
Endocrine System Cancers
Head and Neck Cancers
Urinary Tract Cancers
Bone Marrow Transplants
General Treatment Concerns
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
Cancer Resource List
Resources for Young Adults